The short answer is: most are. The accurate answer is more nuanced. This page gives you the complete legal picture, including what SAHPRA regulates, what it does not, and where the regulatory landscape is heading.
This page is for educational purposes only. It does not constitute legal advice. Consult a qualified South African attorney before making commercial decisions in this space.
Not all peptides sit in the same legal category. The mistake most people make, including some medical professionals, is treating "peptides" as a single regulated class. It is not. Each compound has its own status.
Peptides that have been registered as medicines under SAHPRA fall here, mostly as Schedule 4 substances. These include insulin, all GLP-1 agonists (semaglutide, tirzepatide, liraglutide), and other therapeutic peptides with a registered medicine equivalent in South Africa.
Requires valid prescription from an authorised prescriber. Dispensed by pharmacy only. Cannot be advertised to the public. Selling without a script is a criminal offence under the Medicines Act. GLP-1s carry additional patent infringement risk. Avolvia does not and will not supply Tier 1 compounds.
These compounds are not on any SAHPRA schedule. Not because they are considered safe, but because SAHPRA has never reviewed them for registration as medicines. They exist in a regulatory void, and that void is currently legal to operate in under research and educational framing.
This is the space where the entire South African research compound market operates. Operators including peptides.co.za, BioHck, Ultra Labs, Research Peptides SA, and PrimeSelf have run publicly for years in this framework without enforcement action.
No prescription required. Available to 18+ individuals. Must be marketed as research, laboratory, and educational use only. No medical claims. No human consumption framing. Buyer acknowledges research purpose. Disclaimer signed at point of purchase.
The same compounds as Tier 2, but compounded by a licensed South African pharmacy under Section 22A of the Medicines Act for a specific named patient. Requires a doctor consult, a script, and a compounding pharmacy partnership. Stronger legal position than Tier 2. Avolvia has this as its Plan B if SAHPRA reclassifies Tier 2 compounds.
Avolvia operates exclusively in Tier 2. Every compound we supply is unscheduled under SAHPRA. We do not supply, and will never supply, any Schedule 4 substance, any GLP-1 agonist, or any compound under active patent enforcement.
Semaglutide (Ozempic, Wegovy)
Schedule 4 + active patent + SAHPRA enforcement underway
Tirzepatide (Mounjaro)
Schedule 4 + active patent + SAHPRA enforcement underway
Liraglutide
Schedule 4 registered medicine
Insulin
Schedule 4 registered medicine
Human Growth Hormone (Somatropin)
Schedule 4
IGF-1
Schedule 4 territory
Testosterone / AAS
Schedule 4-5
Honesty matters here. The regulatory landscape is not static.
SAHPRA published an official Communication to Stakeholders stating its intention to declare compounded GLP-1 and GLP-1/GIP agonist medicines undesirable under Section 23 of the Medicines Act. Enforcement of this is now in motion.
Unscheduled research peptides (Tier 2) are not currently targeted. Operators have run publicly for years without enforcement action. The legal void remains open.
SAHPRA is paying attention to the category as a whole. Broader reclassification of research peptides is possible on a 12-36 month horizon. This window is real. It will not be open forever.
The honest position.
You are operating legally under the current regulatory framework. You are operating in a grey zone that could close at any time. You are not breaking the law today. The regulatory direction of travel is toward tighter controls, not looser ones. Anyone operating in this space without a contingency plan is not paying attention. Avolvia is building one.
Unscheduled research compounds do not require a script or doctor consult under current South African law. You are not breaking the law by purchasing them.
Age verification is required at purchase. Avolvia logs this verification for compliance purposes.
You are purchasing for research, educational, or laboratory use only. This is the legal framework within which these compounds are supplied.
These compounds have not been evaluated by SAHPRA for safety, efficacy, or quality for human use. They are not medicines. They are research compounds.
Most compounds supplied by Avolvia are listed on the WADA Prohibited List. Competitive athletes must not use these compounds. This is your responsibility to verify.
The seller's legal risk is determined by how they market the product. The buyer's risk is determined by what they do with it. Know the difference.
The following covers the most commonly researched Tier 2 compounds, their regulatory classification in South Africa, and the biological systems they interact with. This is research context, not medical guidance.
Body Protection Compound 157 is a synthetic pentadecapeptide derived from human gastric juice. It does not appear on any SAHPRA schedule. Research has examined its role in connective tissue repair, angiogenesis, and GI tract healing. It is one of the most studied research peptides globally, with a substantial body of animal model data and a growing number of independent researcher accounts. Not a medicine. Not evaluated by SAHPRA for human use.
Thymosin Beta-4 is a naturally occurring 43 amino acid protein found in virtually all human and animal tissue. The synthetic analogue TB-500 is widely studied for its role in cellular migration, angiogenesis, and anti-inflammatory signalling. Unscheduled in South Africa. Listed on the WADA Prohibited List under S2 Peptide Hormones - competitive athletes should not use this compound. Not a medicine.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). Ipamorelin is a growth hormone secretagogue. Both are unscheduled under SAHPRA - they are not somatropin (human growth hormone) itself, which is Schedule 4. The distinction is important: these compounds stimulate the pituitary to produce endogenous GH rather than replacing it. Both appear on the WADA Prohibited List. Research interest centres on GH pulse amplitude, body composition, and sleep architecture.
Bremelanotide is a melanocortin receptor agonist. In the United States it is FDA-approved as Vyleesi for hypoactive sexual desire disorder. In South Africa it is not a registered medicine under SAHPRA and is therefore unscheduled - making it Tier 2 for research purposes. Its mechanism involves central nervous system melanocortin pathways rather than vascular mechanisms. Note that the US approval pertains specifically to female HSDD. Supply in SA is for research use only.
GHK-Cu (copper peptide) is a naturally occurring tripeptide found in human plasma, urine, and saliva. It is one of the most studied peptides in dermatological research, with data on collagen synthesis, wound healing, and anti-inflammatory activity. It has been used in cosmetic formulations for decades. As a research compound supplied by Avolvia it is formulated for laboratory and research application, not cosmetic use. Unscheduled in South Africa.
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural compound Epithalamin extracted from the pineal gland. Developed in the Soviet Union in the 1980s and researched extensively in Russian clinical literature. Research interest focuses on telomere lengthening, antioxidant activity, and circadian rhythm regulation. It is not registered as a medicine in South Africa and is not on any SAHPRA schedule. Outside mainstream Western clinical research - the evidence base is substantially non-English.
The South African market has legitimate operators and bad ones. Research compound quality varies dramatically. Contaminated or mislabelled compounds do not just produce bad data - they produce dangerous results in any context. These are the verification signals that matter.
A CoA issued by an independent, accredited laboratory - not an internal document from the manufacturer. Should specify: identity confirmation, purity percentage, residual solvent levels, endotoxin load, and enantiomeric purity where applicable. A CoA from the synthesis lab itself is not independent verification.
Compounds produced via solid-phase peptide synthesis (SPPS) to pharmaceutical-grade standards. Not extracted from biological sources (variable composition). Not academic-grade or cosmetic-grade (lower purity standards). Pharmaceutical-grade means ≥99% purity with controlled impurity profiles.
A legitimate Tier 2 supplier never claims compounds treat, cure, prevent, or diagnose any condition. The moment a supplier makes dosing recommendations for human use or frames compounds as treatments, they are operating outside the legal framework. This is a red flag for compliance, and for quality.
Most lyophilised (freeze-dried) peptides are stable at room temperature for short periods, but potency degrades with heat exposure over time. A supplier shipping peptides in standard postal packaging without temperature controls is either not handling pharmaceutical-grade product or does not understand it.
Any supplier unable or unwilling to provide a Certificate of Analysis from an independent lab is supplying unverified product. There is no way to know the purity, identity, or impurity profile of the compound you are receiving. This is a hard disqualifier.
Any supplier openly selling semaglutide, tirzepatide, human growth hormone, or testosterone without prescription framing is operating illegally. If they will cut corners on that, they will cut corners on synthesis quality. The two risks compound each other.
Most research compounds available internationally are manufactured in China or India and shipped directly to consumers. Purchasing from an international supplier versus a local one has meaningful practical and legal differences.
Peptide compounds imported as "research chemicals" or "laboratory reagents" are not specifically targeted by SARS customs. However, any shipment can be held, opened, and inspected. If a compound is unscheduled under SAHPRA it presents no legal issue on inspection - there is no controlled substance violation. If it is a Schedule 4 compound, detention and criminal referral is possible.
Unscheduled research compounds do not require an import permit from SAHPRA. Section 22 of the Medicines Act requires permits for importing scheduled substances. Since Tier 2 compounds are not scheduled, no permit is required for personal research quantities.
There is a practical distinction between importing a small quantity for personal research use and importing bulk stock for commercial resale. SARS and SAHPRA have not published clear quantity thresholds for research compounds. Bulk importation for commercial purposes in a grey-zone product category carries more regulatory exposure than personal quantities.
A South African supplier operating in Tier 2 handles importation, storage, cold-chain logistics, and regulatory positioning as part of their business model. Buying locally means your exposure is the purchase itself - not the importation. It also means purity verification happens before the product reaches you, not after a customs delay.
Note on international orders
Avolvia supplies from within South Africa. All compounds are held locally, cold-chain stored, and shipped domestically. There is no importation risk for Avolvia customers - the compound is already in-country and already verified before it ships to you. This is a deliberate structural choice, not a marketing point.
Avolvia supplies pharmaceutical-grade Tier 2 research compounds to verified 18+ researchers. Third-party tested. Cold-chain delivered. Certificate of Analysis available on most compounds.
View Compounds18+ only. Research use. Not for human consumption.